A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
Clinical trial NCT05364424 · COMPLETED
Trial details
- NCT number
- NCT05364424
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-04
- Primary completion
- 2025-10-15
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.